Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
Go back to Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 55.53 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.53 | 52 Week High | $77.12 | |||
| Open | $55.53 | 52 Week Low | $49.03 | |||
| Day High | $55.53 | P/E | 36.06 | |||
| Day Low | $55.53 | EPS | $1.54 | |||
| Volume | 372 | |||||
